We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Karyopharm Therapeutics
KPTI
$161M
| $7.41M | 0.05% |
47,845
-15,593
| -25% | -$2.26M |
|
327
Thomson Reuters
TRI
$42.7B
| $7.38M | 0.05% |
70,426
-19,230
| -21% | -$1.93M |
|
|
RDUS
328
DELISTED
Radius Health, Inc.
RDUS
| $7.35M | 0.05% |
403,068
+50,501
| +14% | +$1M |
|
|
FMTX
329
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $7.29M | 0.05% |
292,692
+169,688
| +138% | +$4.56M |
|
330
Blink Charging
BLNK
$79.5M
| $7.26M | 0.05% |
176,342
+176,320
| +801,455% | +$6.54M |
|
|
ALLK
331
DELISTED
Allakos
ALLK
| $7.21M | 0.05% |
66,054
-2,897
| -4% | -$289K |
|
332
Tandem Diabetes Care
TNDM
$1.18B
| $7.17M | 0.05% |
73,587
+21,217
| +41% | +$1.89M |
|
|
UMPQ
333
DELISTED
Umpqua Holdings Corp
UMPQ
| $7.15M | 0.05% |
+387,416
| New | +$7.21M |
|
334
American Eagle Outfitters
AEO
$2.98B
| $7.1M | 0.05% |
+189,260
| New | +$6.56M |
|
335
Infosys
INFY
$47.4B
| $7.07M | 0.05% |
333,594
+12,356
| +4% | +$236K |
|
336
W.W. Grainger
GWW
$66B
| $7.03M | 0.05% |
13,966
+4,165
| +42% | +$1.84M |
|
|
ETNB
337
DELISTED
89bio
ETNB
| $6.98M | 0.05% |
+373,473
| New | +$8.34M |
|
338
Zebra Technologies
ZBRA
$12.6B
| $6.91M | 0.05% |
13,053
+1,070
| +9% | +$533K |
|
339
Theravance Biopharma
TBPH
$874M
| $6.91M | 0.05% |
+475,696
| New | +$8.93M |
|
|
GBT
340
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $6.88M | 0.05% |
+196,330
| New | +$7.67M |
|
341
New Oriental
EDU
$7.94B
| $6.87M | 0.05% |
83,866
+61,383
| +273% | +$7.45M |
|
342
Atmos Energy
ATO
$29.7B
| $6.85M | 0.05% |
71,241
-30,798
| -30% | -$3.09M |
|
343
Sutro Biopharma
STRO
$398M
| $6.81M | 0.05% |
36,621
-190
| -0.5% | -$37.2K |
|
344
Dyne Therapeutics
DYN
$4.24B
| $6.8M | 0.05% |
+323,393
| New | +$6.08M |
|
|
HARP
345
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $6.79M | 0.05% |
48,951
+48,948
| +1,631,600% | +$9.34M |
|
346
CNO Financial Group
CNO
$4.96B
| $6.78M | 0.05% |
+287,217
| New | +$7.34M |
|
347
Acadia Pharmaceuticals
ACAD
$4.35B
| $6.72M | 0.05% |
275,560
-23,328
| -8% | -$527K |
|
348
Fidelity National Information Services
FIS
$22.3B
| $6.66M | 0.05% |
47,008
-8,662
| -16% | -$1.29M |
|
349
FedEx
FDX
$73.5B
| $6.63M | 0.05% |
22,207
+4,061
| +22% | +$1.21M |
|
350
Avery Dennison
AVY
$12.5B
| $6.59M | 0.05% |
31,341
+6,544
| +26% | +$1.37M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.